KYMR — Kymera Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.99bn
- $8.30bn
- $39.21m
Brief: Kymera Therapeutics Announces U.S. FDA Fast Track Designation For KT-621, A First-In-Class, Oral STAT6 Degrader For The Treatment Of Atopic Dermatitis
Brief: Kymera Therapeutics Announces Pricing Of Upsized $602 Million Public Offering At $86 Per Share
Kymera Therapeutics slides after launching $500 million share offering
U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico
U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart
Buzz Us Stocks On The Move: Tesla, Warner Bros Discovery, Netflix
U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
Brief: Kymera Therapeutics Says KT-621 Well-Tolerated With No Serious Adverse Events Reported
Kymera Therapeutics rises after positive data for eczema drug
NASDAQ RESUMED AT 07:20 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
U.S. RESEARCH ROUNDUP-ADM, Pinterest, Ul Solutions
Kymera Therapeutics Q3 revenue misses analyst expectations, net loss widens
Brief: Kymera Therapeutics Q3 EPS USD -0.94
Brief: Kymera Therapeutics Announces Late-Breaking Oral Presentations On KT-621, A First-In-Class, Oral Stat6 Degrader, At The European Academy Of Dermatology & Venereology And European Respiratory Society Congresses
U.S. RESEARCH ROUNDUP- aTyr pharma, Clear Secure, Neumora Therapeutics
Kymera Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 revenue misses expectations, net loss widens
U.S. STOCKS ON THE MOVE-Estee Lauder, TC Energy, Cancer test makers